ARTICLE | Financial News

Codiak raises $76.5M in series C

December 1, 2017 10:09 PM UTC

Exosome therapeutics company Codiak BioSciences Inc. (Cambridge, Mass.) raised $76.5 million in an untranched series C round. Existing investors Alaska Permanent Fund, Alexandria Venture Investments, Arch Venture Partners, Fidelity and Flagship Pioneering were joined by new investors Casdin Capital, EcoR1 Capital, Qatar Investment Authority, Sirona Capital and Tavistock Group's Boxer Capital. The deal brings Codiak's total fund-raising since its launch in 2015 to $168.5 million.

President and CEO Doug Williams told BioCentury the cash will allow Codiak to generate clinical data for its lead program, an engineered exosome that delivers an siRNA against K-Ras (KRAS) that is in preclinical development to treat pancreatic cancer. He said the capital would also fund the preclinical development of additional undisclosed exosome therapeutics targeting immuno-oncology indications...

BCIQ Target Profiles

K-Ras (KRAS)